九洲药业: 浙江九洲药业股份有限公司2025年半年度报告摘要

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. reported a profit distribution plan for the first half of 2025, proposing a cash dividend of 2.00 yuan per 10 shares to all shareholders, with no stock increase or bonus shares [1]. Company Overview - The total assets of the company at the end of the reporting period were approximately 10.96 billion yuan, a decrease of 1.55% compared to the end of the previous year [2]. - The net assets attributable to shareholders of the listed company increased by 2.04% to approximately 8.71 billion yuan [2]. - The operating income for the reporting period was approximately 2.87 billion yuan, reflecting a year-on-year increase of 3.86% [2]. - The total profit for the period was approximately 650.31 million yuan, an increase of 17.20% compared to the previous year [2]. - The net profit attributable to shareholders of the listed company was approximately 525.83 million yuan, representing a year-on-year increase of 10.70% [2]. - The net cash flow from operating activities was approximately 845.15 million yuan, a significant increase of 164.50% compared to the same period last year [2]. - The weighted average return on net assets was 6.02%, an increase of 0.48 percentage points from the previous year [2]. - Basic and diluted earnings per share were both 0.59 yuan, up 11.32% from the previous year [2]. - The total number of shareholders at the end of the reporting period was 53,672 [2]. Major Shareholders - The largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., is a domestic non-state-owned legal entity [3]. - Other significant shareholders include Taizhou Gede Industrial Co., Ltd. and individual shareholders such as Hua Lirong and Lin Huilu [3]. - There are noted relationships among some shareholders, indicating that certain individuals are acting in concert [3].